CMS Proposes Letting Part D Plans Switch Biologics To Non-Interchangeable Biosimilars

By Gabrielle Wanneh / November 6, 2023 at 7:02 PM

In a bid to boost uptake of lower-cost biosimilars, CMS is proposing to let Medicare Part D plans substitute reference biologics with biosimilars that haven’t been deemed interchangeable by FDA.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

CMS Proposes Letting Part D Plans Switch Biologics To Non-Interchangeable Biosimilars

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.